XPhyto Therapeutics Hugh Rogers on the fastest and most portable PCR test available

In a recent InvestorIntel interview, Peter Clausi spoke with Hugh Rogers, CEO and Director of XPhyto Therapeutics Corp. (CSE: XPHY | OTCQB: XPHYF) about XPhyto’s rapid point-of-care COVID-19 PCR test system which is very close to commercialization.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Hugh went on to speak on the different types of COVID-19 tests out of which, he said, “PCR test is the gold standard of diagnostics.” He added that XPhyto’s PCR test is less invasive as it is oral and requires minimal equipment and training. The test has been optimized for speed and portability. “What we have designed is we believe to be the fastest and most portable PCR test available…”

To watch the full interview, click here

About XPhyto Therapeutics Corp.

XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

To learn more about XPhyto Therapeutics Corp., click here

Disclaimer: XPhyto Therapeutics Corp. is an advertorial member of InvestorIntel Corp.




Sixth Wave’s Dr Jon Gluckman on the competitive advantages of Molecular Imprint Polymers for the rapid detection of viruses

In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Jon Gluckman, President, CEO and Founder of Sixth Wave Innovations Inc. (CSE: SIXW | OTCQB: ATURF) about the application of their patented Molecular Imprint Polymers (#MIPs) technology for the detection of the COVID-19 virus, the flu and virus detection in general.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Dr. Gluckman went on to say that their patented #MIPs technology can identify molecules and may be used for detection of viruses in general and more specifically for COVID-19. He added, “We are in the phase 2 of our development for a COVID-19 test that would be completely synthetic test based on our molecular imprinted polymer technology.” Sixth Wave was recently awarded funding from the Nova Scotia COVID-19 Response Council for the development of its Accelerated Molecularly Imprinted Polymer (AMIPs™) technology for the rapid detection of viruses such as SARS-CoV-2.

Speaking on the advantages of their synthetic test Dr. Gluckman said that the two test currently used for COVID-19 detection uses biological material which is fragile and uses tremendous infrastructure to support growing of the biological materials. He explained that Sixth Wave’s technology uses synthetic polymers to detect viruses at a very low cost and allows for extended shelf life, minimal storage and handling requirements, and less sensitivity to temperature and light degradation.

To watch the complete interview, click here

About Sixth Wave

Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of commercial roll out of its Affinity cannabinoid purification system, as well as, IXOS®, a line of extraction polymers for the gold mining industry. The Company is in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (AMIPS) label.

Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for detection and separation of viruses, biogenic amines and other pathogens, for which the Company has products at various stages of development.

To learn more about Sixth Wave Innovations Inc., click here

Disclaimer: Sixth Wave Innovations Inc. is an advertorial member of InvestorIntel Corp.




Dr Gluckman on the rapid-detection benefits of Sixth Wave’s virus test kits

“You can think about our polymer almost like an antibody inside a body,” says Dr. Jonathan Gluckman, President, CEO and Founder of Sixth Wave Innovations Inc. (CSE: SIXW | OTCQB: ATURF), in an interview with InvestorIntel’s Tracy Weslosky. “A virus has a size and shape and we create an imprint in our polymer for that exact virus. Then we will detect that directly based on our chemistry,” he continued. “We are working to integrate this into masks and breathalyzers and then we can just utilize the breath, as we all know that’s the main transmission method. If you think about putting a mask on, not only will that mask provide protection, it can also, right there, be the test for COVID-19.”

Dr. Gluckman explained that Sixth Wave’s COVID-19 detection technology is currently under development but the company has successfully launched and commercialized other products with similar properties. The company has received a grant from the Canadian government to work with York University and the CTRI (Centre Technologique des Résidus Industriels) to use its virus detection technology to detect COVID-19 virus in wastewater supplies and in air handling systems.

Highlighting the advantages of Sixth Wave’s COVID-19 test over other tests, Dr. Gluckman also said that the test will be cheaper, faster and easy to use.

To access the complete interview, click here.

Disclaimer: Sixth Wave Innovations Inc. is an advertorial member of InvestorIntel Corp.